Clinical Trials on Erythropoietic Protoporphyria (EPP) in Norway

Total 5 results

Mitsubishi Tanabe Pharma America Inc.

Active, not recruiting

Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

EPP | XLP

United States, Germany, Japan, Spain, Italy, Sweden, Australia, Canada, Norway, United Kingdom
Mitsubishi Tanabe Pharma America Inc.

Completed

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria

EPP | XLP

Spain, United States, Germany, Norway, Italy, Australia, Canada, Japan, Sweden, United Kingdom
Nordlandssykehuset HF
University of Oslo; Norwegian University of Science and Technology; The University... and other collaborators

Recruiting

Clinical Research on Acute Intermittent Porphyria and the Use of Carbohydrate-Rich Diet as a Treatment

Porphyria, Acute Intermittent

Norway
Nordlandssykehuset HF
The Royal Norwegian Ministry of Health

Active, not recruiting

Dental Health, Diet, Inflammation and Biomarkers in Patients With Acute Intermittent Porphyria(AIP)

Acute Intermittent Porphyria

Norway
Alnylam Pharmaceuticals

Completed

EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)

Acute Hepatic Porphyria

United States, Belgium, Bulgaria, France, Italy, Mexico, Spain, Taiwan, United Kingdom, Netherlands, Korea, Republic of, Switzerland, Czechia, Poland, Finland, Australia, Germany, Israel, Norway, South Africa

3

Subscribe